Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

33%

Ph phase_1

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

Phase 2Efficacy & side effects

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (66.7%)

Phase 21 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_1

Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response

NCT02290041

completedphase_1

Study, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence

NCT02292628

completedphase_2

Ketones in Heart Failure - Effects on Cardiac Efficiency

NCT03073356

Clinical Trials (3)

Showing 3 of 3 trials

NCT02290041Phase 1

Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response

Completed

NCT02292628Phase 1

Study, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence

Completed

NCT03073356Phase 2

Ketones in Heart Failure - Effects on Cardiac Efficiency

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3